Furthermore, the methodology was used for CRISPR-based editors to treat amyotrophic lateral sclerosis (ALS), which is due to mutations in the superoxide dismutase 1 (SOD1) gene in a G93A-SOD1 mouse model of ALS (Lim et al., 2020). Here, SOD1 is linked to amyotrophic lateral sclerosis.